Research
Energy balance
Future clinical trials with other incretin mimetics may further emphasize the importance of an obesity phenotype-based approach in treating HFpEF.
Clinicians should stay informed about upcoming trials that may validate obesity phenotype-based treatments.
LimitedQualifiesmedium confidence
Future clinical trials with other incretin mimetics with more potent weight loss and sub-analyses of the SELECT trial may further emphasize the importance of the obesity phenotype-based approach in the treatment of HFpEF.
Why this rating
Based on expert opinion and future research suggestions.
Source
Targeting obesity for therapeutic intervention in heart failure patients
Ryosuke Sato et al. · Expert Review of Cardiovascular Therapy · 2024
DOI 10.1080/14779072.2024.2363395
reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The STEP HFpEF and SELECT trials demonstrated that semaglutide improves clinical outcomes in obese HFpEF patients and reduces cardiovascular and heart failure events in non-diabetic obese patients.Strong
- Obesity-targeted interventions are a novel treatment strategy for heart failure with preserved ejection fraction (HFpEF).Good
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →